Learning Objectives
- Explain the genetics and pathophysiology of the CFTR protein defect.
- Contrast the CFTR function in sweat glands vs. respiratory/GI epithelia.
- Identify multisystem complications (Pulmonary, GI, Reproductive).
- Describe diagnostic methods and modern CFTR modulator therapies.
1. Genetics & Pathophysiology
Genetics: Autosomal recessive; caused by a mutation in the CFTR gene on chromosome 7. The most common mutation is a 3-base pair deletion of phenylalanine at position 508 (ΔF508).
- Mechanism: The ΔF508 mutation leads to a misfolded protein. It is trapped in the Rough ER and degraded, never reaching the cell membrane.
- CFTR Function: An ATP-gated
channel.
- Lungs/GI: Normally secretes
. In CF, decreased
secretion leads to increased ENaC activity → massive
and
reabsorption → dehydrated, thick mucus.
- Sweat Glands: Normally reabsorbs
. In CF,
stays in the duct, preventing
reabsorption → high salt content in sweat.
- Lungs/GI: Normally secretes

2. Clinical Manifestations
| System | Key Findings & Complications |
|---|---|
| Pulmonary | Recurrent infections (S. aureus in kids, P. aeruginosa in adults). Bronchiectasis, nasal polyps, nail clubbing. |
| Gastrointestinal | Meconium ileus in newborns. Pancreatic insufficiency (steatorrhea, ADEK vitamin deficiency), biliary cirrhosis. |
| Reproductive | Males: Infertility due to congenital bilateral absence of vas deferens (CBAVD). Females: Subfertility (thick cervical mucus). |
3. Diagnosis & Management
- Diagnosis: Increased
concentration in pilocarpine-induced sweat test. The newborn screen looks for increased immunoreactive trypsinogen.
- Treatment:
- Mucus Clearance: Chest physiotherapy, dornase alfa (DNase), hypertonic saline.
- Antibiotics: Azithromycin (prevention), Tobramycin (for Pseudomonas).
- CFTR Modulators:
- Potentiators (Ivacaftor): Keep the channel gate open.
- Correctors (Lumacaftor/Tezacafortor): Help the protein fold and reach the surface.
Activity

You must be logged in to post a comment.